undamentalytics Newsletter
Sign in

Lifemd, Inc. revenue

Lifemd, Inc.'s revenue was $194m in fiscal 2025, up 25.3% on the year before. Since fiscal 2012 ($673,778) it has grown at a compound 54.6% a year. Over the last twelve months it was $165m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1111548123793119153155194165
Growth on the year before—+20.0%−11.7%+70.7%+329.8%−29.7%+126.1%+49.8%+199.1%+149.0%+28.2%+28.2%+1.5%+25.3%—
Gross profit0111336102875100134133166142
Gross margin70.3%77.6%75.8%79.7%62.9%72.4%76.0%79.7%76.2%80.6%84.3%87.6%86.2%85.7%86.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Telehealth Subscription Revenue $113M 58.4% ▲ 67.3%
Telehealth $80.8M 41.6% ▼ 1.6%

From Lifemd, Inc.'s 10-K filed March 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Technology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lifemd, Inc. $165m 3.8% 8.6%
Carecloud, Inc. $129m 15.1% 0.8%
American Well Corp $219m -19.0% -7.4%
Definitive Healthcare Corp. $233m -5.0% -0.8%
Optimizerx Corp $98.7m -5.8% 17.0%
Health Catalyst, Inc. $292m -7.5% 0.9%

Compare with peers

Head to head: CCLD vs LFMDAMWL vs LFMDDH vs LFMD

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Lifemd, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lifemd, Inc.